capivasertib,alpelisib,AZD5363
novartis,astrazeneca,otsuka
['alpelisib', 'mbc', 'capivasertib', 'solar-1', 'biomarker']
data from faktion showing an os benefit with capivasertib+fulvestrant for er+ mbc, as well as more-granular biomarker analyses of the solar-1 trial of alpelisib+fulvestrant were presented at #asco22 today. read more about targeting the pi3k pathway here: 
The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal. Tweets by the eds.